Free
Education  |   February 2002
Effects of the Selective H1and H2Histamine Receptor Antagonists Loratadine and Ranitidine on Autonomic Control of the Heart
Author Affiliations & Notes
  • Michael A. Nault, M.Sc.
    *
  • Brian Milne, M.D., M.Sc., F.R.C.P.C.
  • Joel L. Parlow, M.D., M.Sc., F.R.C.P.C.
  • * Medical Student, † Professor, ‡ Associate Professor.
  • Received from the Department of Anesthesiology, Queen's University, Kingston, Ontario, Canada.
Article Information
Education
Education   |   February 2002
Effects of the Selective H1and H2Histamine Receptor Antagonists Loratadine and Ranitidine on Autonomic Control of the Heart
Anesthesiology 2 2002, Vol.96, 336-341. doi:
Anesthesiology 2 2002, Vol.96, 336-341. doi:
HISTAMINE is a hydrophilic autocoid, synthesized by mast cells and basophils, that exerts widespread cardiorespiratory effects through interactions with G-protein–coupled membrane receptors. 1 At least three histamine receptor subtypes have been characterized, all of which are found, to varying degrees, in the heart. Histamine subtype 1 (H1) receptors are found in conductive tissue of the atrioventricular node and slow heart rate by decreasing atrioventricular nodal conduction. 1 Cardiac H1receptors are also found in epicardial coronary vessels, 2 where they mediate vasoconstriction. 2,3 Histamine subtype 2 (H2) receptors are also found in the coronary vasculature, where their vasodilating action opposes that of the H1receptor. 2 Moreover, H2receptors are widely distributed throughout the myocardium and nodal tissue, where they exert positive inotropic and chronotropic effects, respectively. 1,2,4 The third histamine receptor subtype (H3) found in the heart is localized to presynaptic postganglionic sympathetic fibers and is autoinhibitory to presynaptic norepinephrine release. 5,6 
The rich distribution of histamine receptors throughout the myocardium and coronary vasculature predisposes the heart to potential cardioregulatory insult in the face of the massive histamine release that characterizes the type I immediate hypersensitivity (anaphylactic) immune response. 3,7 Use of antihistamines in the acute treatment of anaphylactic shock is directed at blocking further histamine-mediated vasodilation and resulting hemodynamic instability, as well as at reducing respiratory and other systemic complications. 8 As such, the administration of H1receptor blockers remains a cornerstone in the acute treatment of anaphylaxis. The addition of H2receptor antagonists to H1antagonists during acute allergic reactions has been shown to speed resolution of symptoms. 9 However, concerns have been raised about the possible attenuation of H2-mediated increases in inotropy and chronotropy, thereby limiting potential cardioexcitatory compensatory mechanisms. 8 Clinically, this does not appear to be the case, as anaphylactic shock refractory to fluids, vasopressors, and H1antagonists has been reversed with high-dose intravenous H2blockers. 10 However, a dysrhythmogenic effect of ranitidine treatment before anesthesia has also been suggested. 11 
Although questions remain regarding the use of histamine receptor antagonist therapy during anaphylaxis, 8–11 it is also unclear whether histamine contributes to normal physiologic regulation of cardiac function. Widespread and diverse distribution of histamine receptors throughout the myocardium, nodal tissue, and coronary vasculature suggests that these receptors may play a role in the physiologic regulation of the normal healthy heart. Where previous studies have documented no gross hemodynamic effects of antihistamine administration, 12,13 such aggregate measures of cardiovascular function have been shown to be insufficient to detect more subtle effects of some drugs on control of cardiovascular function. 14 This study was designed to determine the effects of the widely used selective H1and H2receptor antagonists loratadine and ranitidine on physiologic autonomic heart rate control in healthy volunteers.
Materials and Methods
Subjects
After obtaining approval from the Queen's University Research Ethics Board and written informed consent, 16 healthy male and female volunteers, aged 21–27 yr, were studied in a randomized, double-blinded, placebo-controlled, crossover protocol. Subjects were excluded on the basis of history or presence of symptoms or physical signs of cardiovascular disease, diabetes, pregnancy and lactation, history of allergy or atopy, current or previous use of tobacco products, documented history of intolerance to either test drug, and intake of any compound affecting cardiovascular or autonomic nervous system function, or gastrointestinal motility.
Experimental Protocol
Continuous, noninvasive blood pressure (BP) was monitored using the volume clamp method (Finapres®2300; Ohmeda; Englewood, CO), and electrocardiogram using lead II (Tektronix 400; Tektronix, Beaverton, OR) for calculation of R-R intervals. Data were acquired during low-light conditions with subjects seated in a semireclined position. A metronome was used to pace respiratory frequency at each subject's resting level, with a minimum frequency of 12 breaths per minute. After a period of quiet rest, 12 min of stable baseline BP and electrocardiogram data were acquired, after which subjects ingested either 20 mg of the H1receptor antagonist loratadine (Claritin®; Schering Canada, Point-Claire, Quebec, Canada), 300 mg of the H2receptor antagonist ranitidine hydrochloride (Gen-Rantidine, Genpharm, Etobicoke, Ontario, Canada), or an inactive placebo. The three treatments were prepared by the hospital research pharmacist in identical gelatin capsules packed with lactose powder. Three hours after drug administration, 12 min of repeat BP and electrocardiogram data were obtained.
Subjects were randomized to receive each of the study drugs on 1 of 3 separate testing days. Testing days were separated by a minimum of 48 h to minimize drug carryover effects. Study drugs were identically packaged, and dosing schedules were determined using computer-generated tables. Dosing codes were prepared and sealed by the hospital research pharmacist until completion of the protocol. Subjects abstained from caffeine, alcohol, tobacco, and heavy physical activity for 12 h before each study session.
Data Acquisition and Analysis
Analog electrocardiogram and BP signals were acquired on-line and digitized using a 12-bit analog–digital converter at a sampling rate of 1,000 Hz (DAS-16®; Metrabyte, Taunton, MA). During digitization, systolic and diastolic BP, as well as the R-R interval, were measured on a beat-by-beat basis. Electrocardiogram data were analyzed using customized software (Richard Hughson, Ph.D., Department of Kinesiology, University of Waterloo, Ontario, Canada). Power spectral analysis of heart rate variability was used to determine indices of the relative sympathetic and parasympathetic influences on the heart. 15 Briefly, a fast Fourier transformation was applied to a string of 512 consecutive R-R intervals (obtained from stationary data) to generate a power spectral curve (in units of milliseconds squared per hertz). By integrating the power in the low-frequency (0–0.15 Hz), high-frequency (0.15–0.50 Hz), and total frequency (0–0.50 Hz) ranges of the spectral curve, indices of parasympathetic (high frequency/total frequency ratio) and sympathetic (low frequency/high frequency ratio) modulation of cardiovascular control were calculated. 15 
Cardiac baroreflex sensitivity was calculated using the spontaneous baroreflex (sequence) method. 16–18 During each recording period, sequences of spontaneously occurring increases or decreases in BP that were accompanied by concordant (i.e.  , baroreflex-mediated) changes in R-R interval were identified. The paired R-R interval and BP sequences were plotted on an x–y curve, and a regression slope was determined for each. The mean regression slope for all sequences represents the spontaneous baroreflex sensitivity, an index of parasympathetically mediated beat-by-beat heart rate control. These values have been shown to reflect those obtained using pharmacologic baroreflex stimulation during resting conditions. 18 
After each data collection session during drug treatment, subjects were questioned regarding the presence of side effects, including sedation, dry mouth, headache, or rash.
Statistical Analysis
Using variance data from previous studies utilizing the same methodology, 14 sample size analysis indicated a need to study at least 12 subjects to detect a 30% change in spontaneous baroreflex sensitivity with a power of 80% and P  < 0.05. Between-drug comparisons, using percent change from baseline for each treatment, were conducted using one-way repeated-measures analysis of variance for normally distributed data (heart rate, BP) and repeated measures on ranks for nonnormally distributed data (heart rate variability data). Where significant differences were found (P  < 0.05), post hoc  analyses were performed using the Tukey method.
Results
Two subjects were withdrawn after enrollment: one on the basis of frequent premature contractions at baseline, making analysis of heart rate variability impossible; the other experienced a pronounced vasovagal episode during a baseline measurement and withdrew. All subjects tolerated the study drugs well, and none reported any adverse drug effects.
Baseline heart rate and BP were similar on all test days and remained unchanged after drug administration (table 1). Baseline measures of autonomic control were also consistent between subjects and within subjects across testing days.
Table 1. R-R Interval and Blood Pressure Data
Image not available
Table 1. R-R Interval and Blood Pressure Data
×
Figure 1depicts a complete set of experiments on a representative subject, showing a reduction in high-frequency power (> 0.15 Hz) only after administration of ranitidine. Overall, neither placebo nor loratadine significantly altered sympathetic or parasympathetic indices of heart rate variability (figs. 2A and B, respectively) or baroreflex sensitivity (fig. 2C). By contrast, raniti-dine decreased the parasympathetic indicator, high frequency/total frequency ratio, by 25% (0.52 ± 0.04 to 0.39 ± 0.04;P  < 0.01;fig. 2B). Likewise, ranitidine reduced baroreflex sensitivity by 23.3% (23.3 ± 2.8 to 17.8 ± 2.1 ms/mmHg;P  < 0.05;fig. 2C). The reduction in parasympathetic indices was accompanied by a concordant increase of 103.8% in the low frequency/high frequency ratio (1.04 ± 0.15 to 2.12 ± 0.55;P  < 0.01;fig. 2A), indicating a strong shift toward sympathetic predominance during conditions of H2receptor blockade with ranitidine.
Fig. 1. Complete set of power spectral curves from one subject on 3 study days. The left column represents baseline measures, and the right column represents data collected 3 h after ingestion of the study drug.
Fig. 1. Complete set of power spectral curves from one subject on 3 study days. The left column represents baseline measures, and the right column represents data collected 3 h after ingestion of the study drug.
Fig. 1. Complete set of power spectral curves from one subject on 3 study days. The left column represents baseline measures, and the right column represents data collected 3 h after ingestion of the study drug.
×
Fig. 2. (A  ) Low/high frequency ratio of heart rate variability (sympathetic indicator); (B  ) High/total frequency ratio of heart rate variability (parasympathetic indicator); and (C  ) spontaneous baroreflex sensitivity (BRS); at baseline (white columns) and 3 h after oral administration of placebo, loratadine, or ranitidine (black columns). Columns represent mean ± SEM. *Significant change from baseline (P  < 0.05).
Fig. 2. (A 
	) Low/high frequency ratio of heart rate variability (sympathetic indicator); (B 
	) High/total frequency ratio of heart rate variability (parasympathetic indicator); and (C 
	) spontaneous baroreflex sensitivity (BRS); at baseline (white columns) and 3 h after oral administration of placebo, loratadine, or ranitidine (black columns). Columns represent mean ± SEM. *Significant change from baseline (P 
	< 0.05).
Fig. 2. (A  ) Low/high frequency ratio of heart rate variability (sympathetic indicator); (B  ) High/total frequency ratio of heart rate variability (parasympathetic indicator); and (C  ) spontaneous baroreflex sensitivity (BRS); at baseline (white columns) and 3 h after oral administration of placebo, loratadine, or ranitidine (black columns). Columns represent mean ± SEM. *Significant change from baseline (P  < 0.05).
×
Discussion
Physiologic regulation of cardiac and hemodynamic function depends on intact neurohumoral and autonomic mechanisms. Accordingly, diverse receptor types, including those for catecholamines, acetylcholine, and autocoids such as histamine and bradykinin, are present throughout cardiac structures. 1–4,6 It is well recognized that the heart is a target organ in anaphylaxis, 7 yet localization of histamine receptors to the myocardium, coronary vessels, and nodal tissue suggests that modulation of physiologic cardiac control, possibly by resting concentrations of circulating histamine, may also be a function of cardiac histamine receptors.
Results of this study, indicating significant changes in cardiac autonomic balance after administration of ranitidine in the absence of gross hemodynamic changes, underscores the insight that indices of autonomic control can contribute to a comprehensive understanding of cardiovascular regulation. To our knowledge, this study represents the first investigation of the role of histamine receptor subtypes in resting autonomic control of the cardiovascular system. The contribution of histamine to autonomic heart rate control was investigated by selective pharmacologic antagonism of H1and H2receptors. To minimize the side effects common to first-generation H1blockers, we investigated potential H1-mediated effects with the second-generation H1antagonist loratadine. Loratadine is a tricyclic antihistamine that displays selective peripheral H1antagonism and lacks anticholinergic and central nervous system side effects characteristic of the first-generation H1blockers. 19 Potential H2receptor–mediated contributions to autonomic cardiovascular control were characterized using the specific H2receptor antagonist ranitidine. Clinically, H2receptor antagonists are used to inhibit H2-mediated gastric acid secretion in the treatment of peptic ulcers and dyspepsia; however, these antagonists have also been shown to bind H2receptors in the myocardium and coronary vasculature. 20–23 H2receptors are also found in the central nervous system. Although ranitidine does cross the blood–brain barrier, central side effects are rare and generally confined to the elderly and patients with impaired hepatic or renal function. 24 However, a central, rather than end-organ, effect of ranitidine on brainstem cardiovascular integration cannot be ruled out.
Both loratadine and ranitidine are available in an oral preparation, facilitating their comparison in a double-blinded protocol. Drugs were administered at twice the usual therapeutic dose to achieve near-complete receptor antagonism. The time between drug administration and repeat electrocardiogram and BP sampling was based on a time-to-peak plasma concentration of 1.0–1.5 h for loratadine 25 and 2–3 h for ranitidine. 26 Percent maximal plasma concentrations are therefore similar at 3 h, given half lives of 7.8–14.4 and 4.8 ± 0.3 h for loratadine and ranitidine, respectively. 25,26 
In addition to the presence of cardiac H1and H2receptor subtypes, a cardiac H3histamine receptor subtype is also recognized. 5,6 Although a number of H3-specific antagonists have been developed [thioperamide, clobenpropit, (R)-α-methylhistamine], these agents are used exclusively in basic research and have not yet been made available for clinical use. This study was therefore limited to investigation of potential H1- and H2-mediated effects.
The results of this study suggest that basal autonomic control of the normal healthy heart is not influenced by cardiac H1receptor stimulation, as H1antagonism with loratadine did not alter indices of autonomic heart rate regulation. By contrast, the reduction in parasympathetic measures and shift toward sympathetic predominance after ranitidine suggests a basal level of H2receptor activation in the normal healthy heart that enhances parasympathetic cardiac activity, possibly by suppressing tonic sympathetic drive. 27 The finding of a relative increase in cardiac sympathetic influence on heart rate after H2blockade supplements previous work that demonstrated a prolongation of norepinephrine-mediated cardiac stimulation during H2receptor blockade. 28 In addition, a ranitidine-mediated positive inotropic effect has been shown in the absence of gross changes in heart rate or BP in young healthy males. 29 
Although we have demonstrated a shift toward cardiac sympathetic predominance after H2blockade with ranitidine, conflicting case report data allude to an enhancement of parasympathetic cardiac input, including bradydysrhythmias, 30 atrioventricular block, 31 or asystole 32 after administration of ranitidine. The additional finding that these hemodynamic responses were reversed with the muscarinic antagonist atropine 30,31 emphasizes their likely parasympathomimetic origin. These effects are in keeping with experimental evidence showing an inhibitory effect of H2blockers on the cholinesterase enzyme. 33,34 However, such effects are not evident clinically in healthy people, and the majority of the aforementioned cases involved elderly patients presenting with concomitant cardiovascular, renal, or gastrointestinal disease and variably receiving multiple medications.
Two further explanations for the observed shift toward sympathetic predominance after administration of ranitidine have been considered. First, certain H2blockers (i.e.  , burimamide) show partial agonist effects, yet these findings are not uniformly attributable to all H2antagonists. 35 Moreover, partial agonist activity has not been reported for ranitidine, making this explanation for the cardiac sympathetic prevalence after administration of ranitidine unlikely. Second, H2antagonists demonstrate cross-reactivity at histamine H3receptors. 36 Because H3receptors are inhibitory to presynaptic norepinephrine release from sympathetic fibers in the heart, 5,6,36 blockade of these receptors by ranitidine could result in uninhibited sympathetic outflow. 28 It has been speculated that basal H3-mediated contributions to cardiovascular control are minimal, increasing only during episodes of cardiac stress such as myocardial ischemia. 5,37 Thus, H3receptor inhibition may become particularly relevant in patients at risk for myocardial ischemia, where cardiac norepinephrine concentrations are increased and the threshold for dysrhythmias is reduced. 37 Additional work is required to fully elucidate the clinical implications of these findings.
Although the current study documented effects in healthy resting volunteers, the clinical implications of this work are particularly relevant in situations of heightened histamine release, either related to drug administration during anesthesia or, in the extreme, during anaphylactic reactions. The common practice of treatment with H2antagonists before anesthesia to increase gastric pH could potentially increase the risk of disrupted autonomic cardiac control and resultant cardiac dysrhythmias in the event of an allergic response 11 or myocardial ischemia. 37 On the other hand, combined H1and H2receptor blockade have been shown to be more effective that H1receptor antagonism alone in reducing histamine-related cardiorespiratory disturbances during anesthesia. 38,39 Future studies are needed to extend the findings of this investigation to conditions of heightened plasma histamine concentrations, including documenting the effects of combined H1and H2blockade on autonomic balance, in the absence of and during conditions of heightened histamine release.
In summary, our findings suggest that cardiac H1receptor stimulation by circulating histamine does not alter autonomic control of heart rate in healthy resting subjects. By contrast, H2receptor antagonism with ranitidine led to a decrease in indices of parasympathetic modulation of heart rate, suggesting a possible role of histamine receptors in resting autonomic balance. The implications of these findings to the perioperative setting or during conditions of histamine release merit further study.
The authors thank Nicole Avery, M.Sc. (Queen's University, Kingston, Ontario, Canada), for assistance with data acquisition and analysis.
References
Hattori Y: Cardiac histamine receptors: Their pharmacological consequences and signal transduction pathways. Methods Find Exp Clin Pharmacol 1999; 21: 123–31Hattori, Y
Bristow MR, Ginsburg R, Harrison DC: Histamine and the human heart: The other receptor system. Am J Cardiol 1982; 49: 249–50Bristow, MR Ginsburg, R Harrison, DC
Baumann G, Felix SB, Schrader J, Heidecke CD, Riess G, Erhardt WD, Ludwig L, Loher U, Sebening F, Blomer H: Cardiac contractile and metabolic effects mediated via the myocardial H2 receptor adenylate cyclase system: Characterization of two new specific H2-receptor agonists, impromidine and dimaprit, in the guinea pig and human myocardium. Res Exp Med 1981; 179: 81–98Baumann, G Felix, SB Schrader, J Heidecke, CD Riess, G Erhardt, WD Ludwig, L Loher, U Sebening, F Blomer, H
Watkins J, Dargie HJ, Brown MJ, Krikler DM, Dollery CT: Effects of histamine type 2 receptor stimulation on myocardial function in normal subjects. Br Heart J 1982; 47: 539–45Watkins, J Dargie, HJ Brown, MJ Krikler, DM Dollery, CT
Imamura M, Poli E, Omoniyi AT, Levi R: Unmasking of activated histamine H3-receptors in myocardial ischemia: Their role as regulators of exocytotic norepinephrine release. J Pharmacol Exp Ther 1994; 271: 1259–66Imamura, M Poli, E Omoniyi, AT Levi, R
Malinowska B, Godlewski G, Schlicker E: Histamine H3 receptors-general characterization and their function in the cardiovascular system. J Physiol Pharmacol 1998; 49: 191–211Malinowska, B Godlewski, G Schlicker, E
Capurro N, Levi R: The heart as a target organ in systemic allergic reactions: Comparison of cardiac anaphylaxis in vivo and in vitro. Circ Res 1975; 36: 520–8Capurro, N Levi, R
Brown AFT: Therapeutic controversies in the management of acute anaphylaxis. J Accid Emerg Med 1998; 15: 89–95Brown, AFT
Lin RY, Curry A, Pesola, GR, Knight RJ, Lee H-S, Bakalchuk L, Tenenbaum C, Westfal, RE: Improved outcomes in patients with acute allergic syndromes who are treated with combined H1 and H2 antagonists. Ann Emerg Med 2000; 36: 462–8Lin, RY Curry, A Pesola, GR Knight, RJ Lee, H-S Bakalchuk, L Tenenbaum, C Westfal, RE
Lieberman P: The use of antihistamines in the prevention and treatment of anaphylaxis and anaphylactoid reactions. J Allergy Clin Immunol 1990; 86: 684–6Lieberman, P
Patterson L, Milne B: Latex anaphylaxis causing heart block: Role of ranitidine. Can J Anesth 1999; 46: 776–8Patterson, L Milne, B
Hinrichsen H, Halabi A, Kirch W: Hemodynamic effects of different H2-receptor antagonists. Clin Pharmacol Ther 1990; 48: 302–8Hinrichsen, H Halabi, A Kirch, W
Hughes DG, Dowling EA, DeMeersman RE, Garnett WR, Karnes HT, Garnett WR, Karnes HT: Cardiovascular effects of H2-receptor antagonists. J Clin Pharmacol 1989; 29: 472–7Hughes, DG Dowling, EA DeMeersman, RE Garnett, WR Karnes, HT Garnett, WR Karnes, HT
Dagnone AJ, Parlow JL: Effects of inhaled albuterol and ipratropium bromide on autonomic control of the cardiovascular system. Chest 1997; 111: 1514–8Dagnone, AJ Parlow, JL
Pomeranz B, Macaulay RJ, Caudill MA, Kutz I, Adam D, Gordon D, Kilborn KM, Barger AC, Shannon DC, Cohen RJ: Assessment of autonomic function in humans by heart rate spectral analysis. Am J Physiol 1985; 248: H151–3Pomeranz, B Macaulay, RJ Caudill, MA Kutz, I Adam, D Gordon, D Kilborn, KM Barger, AC Shannon, DC Cohen, RJ
Bertinieri G, Di Rienzo M, Cavallazzi A, Ferrari AU, Pedotti A, Mancia G: A new approach to analysis of the arterial baroreflex. J Hyperten 1985; 3: S79–81Bertinieri, G Di Rienzo, M Cavallazzi, A Ferrari, AU Pedotti, A Mancia, G
Blaber AP, Yamamoto Y, Hughson RL: Methodology of spontaneous baroreflex relationship assessed by surrogate data analysis. Am J Physiol 1995; 268: 1682–7Blaber, AP Yamamoto, Y Hughson, RL
Parlow JL, Viale JP, Annat G, Hughson R, Quintin L: Spontaneous cardiac baroreflex activity in humans: Comparison with pharmacological responses. Hypertension 1995; 25: 1058–68Parlow, JL Viale, JP Annat, G Hughson, R Quintin, L
Simons FER: Loratadine, a non-sedating H1-receptor antagonist (antihistamine). Ann Allergy 1989; 63: 266–8Simons, FER
MacLeod KM, Wenkstern D, McNeill JH: Irreversible antagonism of histamine H2 receptors in guinea-pig myocardium. Eur J Pharmacol 1986; 124: 331–6MacLeod, KM Wenkstern, D McNeill, JH
Vleeming W, van Rooij HH, Wemer J, Porsius AJ: Characterization and modulation of antigen-induced effects in isolated rat heart. J Cardiovasc Pharmacol 1991; 18: 556–65Vleeming, W van Rooij, HH Wemer, J Porsius, AJ
Yazawa K, Abiko Y: Modulation by histamine of the delayed outward potassium current in guinea-pig ventricular myocytes. Br J Pharmacol 1993; 109: 142–7Yazawa, K Abiko, Y
Bertaccini G, Poli E, Corruzi G: In vitro effects of H2-receptor antagonism on the cardiovascular system. Eur J Clin Inv 1995; 25: 19–26Bertaccini, G Poli, E Corruzi, G
Vial T, Goubier C, Bergeret A, Cabrera F, Evreux JC, Descotes J: Side effects of ranitidine. Drug Saf 1991; 6: 94–117Vial, T Goubier, C Bergeret, A Cabrera, F Evreux, JC Descotes, J
Haria M, Fitton A, Peters DH: Loratadine: A reappraisal of its pharmacological properties and therapeutic use in allergic disorders. Drugs 1994; 48: 617–37Haria, M Fitton, A Peters, DH
Lauritsen K, Laursen LS, Rask-Madsen J: Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (part II). Clin Pharmacokinet 1990; 19: 94–125Lauritsen, K Laursen, LS Rask-Madsen, J
Levy MN: Sympathetic-parasympathetic interactions in the heart. Circ Res 1971; 29: 437–45Levy, MN
Gross SS, Guo ZG, Levi R, Bailey WH, Chenouda AA: Release of histamine by sympathetic nerve stimulation in the guinea pig heart and modulation of adrenergic responses: A physiological role for cardiac histamine? Circ Res 1984; 54: 516–26Gross, SS Guo, ZG Levi, R Bailey, WH Chenouda, AA
Meyer EC, Sommers DK, van Wyk M, Avenant JC: Inotropic effects of ranitidine. Eur J Clin Pharmacol 1990; 39: 301–3Meyer, EC Sommers, DK van Wyk, M Avenant, JC
Camarri E, Chirone E, Fanteria G, Zocchi M: Ranitidine induced bradycardia. Lancet 1982; 2: 160Camarri, E Chirone, E Fanteria, G Zocchi, M
Johnson WS, Miller DR: Ranitidine and bradycardia. Ann Inter Med 1988; 108: 493Johnson, WS Miller, DR
Hart AM: Cardiac arrest associated with ranitidine. BMJ 1989; 299: 519Hart, AM
Gwee MCE, Cheah LS: Actions of cimetidine and ranitidine at some cholinergic sites: Implications in toxicology and anesthesia. Life Sci 1986; 39: 383–8Gwee, MCE Cheah, LS
Tanner LA, Arrowsmith JB: Bradycardia and H2 antagonists. Ann Intern Med 1988; 109: 434–5Tanner, LA Arrowsmith, JB
Alewijnse AE, Smit MJ, Hoffmann M, Verzijl D, Timmerman H, Leurs R: Constitutive activity and structural instability of the wild-type human H2 receptor. J Neurochem 1998; 71: 799–807Alewijnse, AE Smit, MJ Hoffmann, M Verzijl, D Timmerman, H Leurs, R
Arrang JM, Garbarg M, Schwartz JC: Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature 1983; 302: 832–7Arrang, JM Garbarg, M Schwartz, JC
Levi R, Smith NC: Histamine H(3)-receptors: A new frontier in myocardial ischemia. J Pharmacol Exp Ther 2000; 292: 825–30Levi, R Smith, NC
Hosking MP, Lennon RL, Gronert GA: Combined H1 and H2 receptor blockade attenuates the cardiovascular effects of high-dose atracurium for rapid sequence endotracheal intubation. Anesth Analg 1988; 67: 1089–92Hosking, MP Lennon, RL Gronert, GA
Lorenz W, Duda D, Dick W, Sitter H, Doenicke A, Black A, Weber D, Menke H, Stinner B, Junginger T: Incidence and clinical importance of perioperative histamine release: Randomised study of volume loading and antihistamines after induction of anaesthesia. Lancet 1994; 343: 933–40Lorenz, W Duda, D Dick, W Sitter, H Doenicke, A Black, A Weber, D Menke, H Stinner, B Junginger, T
Fig. 1. Complete set of power spectral curves from one subject on 3 study days. The left column represents baseline measures, and the right column represents data collected 3 h after ingestion of the study drug.
Fig. 1. Complete set of power spectral curves from one subject on 3 study days. The left column represents baseline measures, and the right column represents data collected 3 h after ingestion of the study drug.
Fig. 1. Complete set of power spectral curves from one subject on 3 study days. The left column represents baseline measures, and the right column represents data collected 3 h after ingestion of the study drug.
×
Fig. 2. (A  ) Low/high frequency ratio of heart rate variability (sympathetic indicator); (B  ) High/total frequency ratio of heart rate variability (parasympathetic indicator); and (C  ) spontaneous baroreflex sensitivity (BRS); at baseline (white columns) and 3 h after oral administration of placebo, loratadine, or ranitidine (black columns). Columns represent mean ± SEM. *Significant change from baseline (P  < 0.05).
Fig. 2. (A 
	) Low/high frequency ratio of heart rate variability (sympathetic indicator); (B 
	) High/total frequency ratio of heart rate variability (parasympathetic indicator); and (C 
	) spontaneous baroreflex sensitivity (BRS); at baseline (white columns) and 3 h after oral administration of placebo, loratadine, or ranitidine (black columns). Columns represent mean ± SEM. *Significant change from baseline (P 
	< 0.05).
Fig. 2. (A  ) Low/high frequency ratio of heart rate variability (sympathetic indicator); (B  ) High/total frequency ratio of heart rate variability (parasympathetic indicator); and (C  ) spontaneous baroreflex sensitivity (BRS); at baseline (white columns) and 3 h after oral administration of placebo, loratadine, or ranitidine (black columns). Columns represent mean ± SEM. *Significant change from baseline (P  < 0.05).
×
Table 1. R-R Interval and Blood Pressure Data
Image not available
Table 1. R-R Interval and Blood Pressure Data
×